临床病理和分子特征促进PD-L1表达在早期肺腺癌和状细胞癌的肺腺癌和状细胞癌

相关实验视频

Updated: Jul 12, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Atsushi Ito^1,2, Tomohito Tarukawa³, Yuta Suzuki⁴

¹Respiratory Center, Department of Thoracic Surgery, Matsusaka Municipal Hospital, Matsusaka, Japan; mchi.atsushi@city-hosp.matsusaka.mie.jp.

Anticancer research

|November 1, 2023

概括

这项研究揭示了肺腺癌和状细胞癌之间编程细胞死亡配体-1 (PD-L1) 表达的关键差异. 这些发现对于理解非小细胞肺癌中对免疫检查点抑制剂的反应至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子病理学分子病理学

背景情况:

非小细胞肺癌 (NSCLC) 亚型,肺腺癌 (LUAD) 和肺状细胞癌 (LSCC) 在早期切除性疾病中很常见.
免疫检查点抑制剂 (ICI) 作为辅助疗法,有望改善肺癌患者的术后结果.
了解编程细胞死亡联体-1 (PD-L1) 表达对于优化在LUAD和LSCC中的ICI疗效至关重要.

研究的目的:

为了比较分析与LUAD和LSCC中PD-L1表达相关的临床病理特征.
调查PD-L1表达和这些NSCLC亚型中的瘤驱动突变之间的关系.

主要方法:

对289名经过手术切除的LUAD和66名LSCC患者的回顾性分析.
对PD-L1表达水平和相关临床病理因素的比较评估.
探索PD-L1表达和驱动突变中的遗传变异之间的相关性.

主要成果:

在LUAD和LSCC之间,PD-L1表达模式显著不同.
在LUAD中,PD-L1表达受到男性性别,吸烟史,侵入性病理和疾病进展的影响.
这些因素与LSCC中的PD-L1表达之间没有发现显著的关联;PD-L1分布与LUAD中的驱动基因突变有所不同.

结论:

临床病理学和分子区别存在于关于PD-L1表达的LUAD和LSCC之间.
这些差异可能会影响PD-L1向治疗在不同NSCLC亚型中的有效性.

关键词:

肺部腺癌是肺部的癌症.驱动性基因突变驱动性基因突变免疫检查点抑制剂免疫检查点抑制剂肺状细胞癌是肺的状细胞癌.编程细胞死亡连接剂-1

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...